CD274 and cancer: Thus, in terms of clinically meaningful surrogate endpoints to estimate the activity of anti-PD-1 and anti-PD-L1 in treating advanced cancers such as esophageal or G/GEJ cancer, as the current study showed, improving the OS post-treatment with PD-1/PD-L1 inhibitors could provide important information on optimal treatment modalities.